In few years the scenario of metastatic prostate carcinoma treatment has radically changed due to improved knowledge of those mechanisms responsible of prostatic cancer cells survival and proliferation. Five new therapeutic agents (abiraterone acetate, enzalutamide, cabazitaxel, radium-223, sipuleucel-T), all able to improve overall survival, have been introduced in the management of metastatic castration-resistant prostate cancer. Moreover, recent evidences showed that adding docetaxel chemotherapy or abiraterone acetate to androgen deprivation therapy significantly increases overall survival of de novo castration-sensitive metastatic prostate cancer patients. Due to this rapid therapeutic evolution clinicians face one crucial challenge: the choice of the best treatment sequencing. In particular, there are no prospective data to guide clinical decision in patients with progressive disease after docetaxel or abiraterone acetate treatment for castration sensitive disease. In this review we provide an overview of the therapeutic agents available for both castration-sensitive and castration-resistant prostate cancer. We propose some biological and clinical insights helpful in selecting the most appropriate treatment for patients progressing after metastatic castration-sensitive prostate cancer treatment with docetaxel or abiraterone acetate.
Cancer treatment reviews. 2019 Jan 07 [Epub ahead of print]
Marcello Tucci, Orazio Caffo, Consuelo Buttigliero, Carla Cavaliere, Carmine D'aniello, Massimo Di Maio, Stefania Kinspergher, Francesca Maines, Mimma Rizzo, Sabrina Rossetti, Antonello Veccia, Giorgio Vittorio Scagliotti, Gaetano Facchini
Division of Medical Oncology, San Luigi Gonzaga Hospital, Department of Oncology, University of Turin, Orbassano, Turin, Italy., Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy., UOC of Medical Oncology, ASL NA3 Sud Ospedali Riuniti Area Nolana, Gragnano (NA), Italy., Division of Medical Oncology, AORN dei Colli Ospedali Monaldi-Cotugno-CTO, Napoli, Italy., Division of Medical Oncology, Ordine Mauriziano Hospital, Department of Oncology, University of Turin, Turin, Italy., Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy., Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy. Electronic address: .